Malaysia-based Hovid seeks US FDA nod for tocotrienols


PETALING JAYA: Investors may have overlooked Hovid Bhd’s pharmaceutical business and efforts to register tocotrienols (a type of Vitamin E) as a US Food and Drug Administration (FDA)-approved drug, said CIMB Investment Bank Bhd in a report.

It is currently sold as a dietary supplement under the brand name “Tocovid” but unlike drugs, dietary supplements cannot make the claim of being able to prevent, treat or cure illnesses due to regulatory restrictions.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Business , hovid , drugs

Next In Business News

BPMB provides RM97.63mil financing facility to Johor's Coronade Properties
GDB announces board realignment to head expansion into East Malaysia
Velesto divests NAGA 3 for RM258mil
Bursa Malaysia closes higher for fourth consecutive session
PTT Synergy accepts RM35.88mil construction job from Sime Darby Property
Carimin Petroleum unit bags RM33.98mil PETRONAS Gas contract
Malaysia's non-life insurance segment outlook remains stable - AM Best
Palm oil industry to remain stable in 2026, focusing on R&D, yield improvement - Johari
DNeX to be included in F4GBM, F4GBMS indices from Dec 22
Malakoff says operations at Tanjung Bin unaffected after accident

Others Also Read